While the same treatment is not sufficient to reduce the size of pancreatic tumors (22), strategies that potentiated SASP production, such as the use of EZH2 inhibitors, increased the infiltration of NK and T cells and resulted in a more complete antitumoral response (23). The gene discussed is EZH2; the disease is pancreatic neoplasm.